Results
tumor, pain
TUMOR, SIDE EFFECT
A total of 13 patients were enrolled in the study between 2006 and 2013. Eight patients were evaluable for the primary endpoint having completed two consecutive PET-CT scans necessary to evaluate tumor response. Five patients were not evaluable for the following reasons: never took naltrexone, significant pain which needed opioid use after consent of study, naltrexone discontinued after the first dose due to side effect (hot flash), or never followed up after study consent.